A 48-year-old woman, who had an outside diagnosis of “peripheral T-cell lymphoma” based on a needle biopsy of a peripancreatic lesion 10 months before, presented with hypercalcemia (15.3 mg/dL) and metabolically active lymphadenopathy after receiving 6 cycles of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) and BEAM (carmustine, etoposide, cytarabine, and melphalan) myeloablative therapy with autologous stem cell transplantation. A few months after her initial workup, she was found to have positive human T-cell leukemia virus type 1 (HTLV-1)/HTLV-2 antibody testing. A bone marrow biopsy was performed given the clinical concern for disease relapse. The core biopsy showed a 50% cellular marrow with a focal loose paratrabecular aggregate (panel A, circle; hematoxylin and eosin stain, original magnification ×20) composed of histiocytes, plasma cells, small lymphocytes, and highly pleomorphic large atypical cells with deeply convoluted nuclei (panels A-B; hematoxylin and eosin stain, original magnification ×40 [B]). Some pleomorphic cells were individually infiltrating in an interstitial fashion. The pleomorphic cells were positive for CD3, CD25 (panels C-D; immunohistochemistry stain, original magnification ×40), and CD4 and negative for CD5 and CD8 by immunohistochemistry. Around the aggregate, there was osteoclastic, bone-chewing activity (arrows). Polymerase chain reaction confirmed the presence of HTLV-1. Thus, a diagnosis of adult T-cell leukemia/lymphoma (ATLL) was rendered.
This case clearly illustrates the characteristic morphology and clinicopathologic correlation of hypercalcemia and bone destruction. Osteolytic bone resorption is a very common phenomenon in ATLL, which likely results in hypercalcemia in this rare aggressive neoplasm.
A 48-year-old woman, who had an outside diagnosis of “peripheral T-cell lymphoma” based on a needle biopsy of a peripancreatic lesion 10 months before, presented with hypercalcemia (15.3 mg/dL) and metabolically active lymphadenopathy after receiving 6 cycles of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) and BEAM (carmustine, etoposide, cytarabine, and melphalan) myeloablative therapy with autologous stem cell transplantation. A few months after her initial workup, she was found to have positive human T-cell leukemia virus type 1 (HTLV-1)/HTLV-2 antibody testing. A bone marrow biopsy was performed given the clinical concern for disease relapse. The core biopsy showed a 50% cellular marrow with a focal loose paratrabecular aggregate (panel A, circle; hematoxylin and eosin stain, original magnification ×20) composed of histiocytes, plasma cells, small lymphocytes, and highly pleomorphic large atypical cells with deeply convoluted nuclei (panels A-B; hematoxylin and eosin stain, original magnification ×40 [B]). Some pleomorphic cells were individually infiltrating in an interstitial fashion. The pleomorphic cells were positive for CD3, CD25 (panels C-D; immunohistochemistry stain, original magnification ×40), and CD4 and negative for CD5 and CD8 by immunohistochemistry. Around the aggregate, there was osteoclastic, bone-chewing activity (arrows). Polymerase chain reaction confirmed the presence of HTLV-1. Thus, a diagnosis of adult T-cell leukemia/lymphoma (ATLL) was rendered.
This case clearly illustrates the characteristic morphology and clinicopathologic correlation of hypercalcemia and bone destruction. Osteolytic bone resorption is a very common phenomenon in ATLL, which likely results in hypercalcemia in this rare aggressive neoplasm.
For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.
![A 48-year-old woman, who had an outside diagnosis of “peripheral T-cell lymphoma” based on a needle biopsy of a peripancreatic lesion 10 months before, presented with hypercalcemia (15.3 mg/dL) and metabolically active lymphadenopathy after receiving 6 cycles of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) and BEAM (carmustine, etoposide, cytarabine, and melphalan) myeloablative therapy with autologous stem cell transplantation. A few months after her initial workup, she was found to have positive human T-cell leukemia virus type 1 (HTLV-1)/HTLV-2 antibody testing. A bone marrow biopsy was performed given the clinical concern for disease relapse. The core biopsy showed a 50% cellular marrow with a focal loose paratrabecular aggregate (panel A, circle; hematoxylin and eosin stain, original magnification ×20) composed of histiocytes, plasma cells, small lymphocytes, and highly pleomorphic large atypical cells with deeply convoluted nuclei (panels A-B; hematoxylin and eosin stain, original magnification ×40 [B]). Some pleomorphic cells were individually infiltrating in an interstitial fashion. The pleomorphic cells were positive for CD3, CD25 (panels C-D; immunohistochemistry stain, original magnification ×40), and CD4 and negative for CD5 and CD8 by immunohistochemistry. Around the aggregate, there was osteoclastic, bone-chewing activity (arrows). Polymerase chain reaction confirmed the presence of HTLV-1. Thus, a diagnosis of adult T-cell leukemia/lymphoma (ATLL) was rendered. / This case clearly illustrates the characteristic morphology and clinicopathologic correlation of hypercalcemia and bone destruction. Osteolytic bone resorption is a very common phenomenon in ATLL, which likely results in hypercalcemia in this rare aggressive neoplasm.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/8/10.1182_blood-2017-11-817106/4/m_blood817106f1.jpeg?Expires=1765950789&Signature=tGP02BVl~WIbvgKAxvJU8oJBs26mYz2kj6~hJwBQnAai3yg9DSyfxSm3sv9oVC3ZAl17SgWo931AH~6IQcTIpBJpJayq1jWm7qAlV0DB~FvKclHLgQc7jLiNY0HouL~hIGP-xAHvo4aiY-H-WkRrEgtTDIq4VP6sVmE5JUvnmwpWT5MCmbakU3NUv6o3378CIjd7yge5Yj3GGwGzvBvX~hkJfzn8P~vGsHk567B-Gnb8WM6QxzgPnE107NxxlvLlTIX53X6cbta8p43EndOkV1f7DJ2WyUIykwg4~YOXHhfsX~5ib~zPeLypxEVtBnuB9ZQ2fpi43Sybf48iAo2YiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal